Thus, the aim of our study was to underline the cardioprotective benefits of SGLT-2 inhibitors using clinical data and to highlight the importance of the preventive treatment of patients with T2DM, who represent a population at high risk for heart failure. This evidence concerns the gene SLC5A2 and heart failure.